GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Quality Rank

Argent Biopharma (LSE:RGT) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Argent Biopharma Quality Rank Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.